Advertisement

Topics

Genentech seeks FDA approval for Venclexta for AML

04:07 EDT 13 Jul 2018 | Pharmaceutical Business Review

Roche’s Genentech has submitted a supplemental New Drug Application (sNDA) to the US Food and Drug Administration (FDA) for Venclexta (venetoclax), in combination with either a hypomethylating agent or low dose cytarabine (LDAC), for the treatment of acute myeloid leukemia (AML) in previously untreated patients who are ineligible for intensive chemotherapy.

Original Article: Genentech seeks FDA approval for Venclexta for AML

NEXT ARTICLE

More From BioPortfolio on "Genentech seeks FDA approval for Venclexta for AML"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...